LifeTech Scientific Corporation (HK:1302)
:1302
Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.47 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)26.58M
Market Cap
HK$6.91B
Enterprise ValueHK$5.55B
Total Cash (Recent Filing)HK$1.20B
Total Debt (Recent Filing)HK$8.04M
Price to Earnings (P/E)43.0
Beta0.90
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.79
Price to Sales (P/S)4.58
P/FCF Ratio12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage materially reduces financial risk and preserves financing optionality. Over the next 2–6 months this conservatism supports stable operations, capacity to fund clinical/commercial investments, and resilience to reimbursement or demand shocks without needing urgent external financing.
Revenue Re-accelerationA strong top-line rebound indicates improving product adoption or market traction that can underpin durable revenue base expansion. If the drivers (unit growth, distribution gains) persist, this momentum supports scalable sales, stronger bargaining power with hospitals, and longer-term procedure share gains.
Improved Free Cash FlowHigher free cash flow and close conversion to net income enhance internal funding for R&D, capital expenditure, and training programs tied to device adoption. Sustained FCF strengthens self-funded growth potential and reduces reliance on external capital over the medium term.
Bears Say
Margin CompressionSteep margin erosion signals worsening profitability and weaker earnings leverage versus historical peaks. Structural pressures—pricing, product mix, higher costs or investments—could persist, limiting ability to convert revenue gains into sustainable net income and restricting reinvestment capacity.
Declining ROEFalling return on equity reflects reduced capital efficiency and weaker shareholder returns. Persistently low ROE undermines the case for large equity capital bases, may pressure management to restructure or reallocate capital, and could constrain long-term value creation absent margin or growth recovery.
Volatile Cash ConversionInconsistent cash conversion reduces predictability of funding for R&D, commercialization, and capex. Volatility raises the risk that management will need external financing in downturns or delay strategic initiatives, weakening the company’s ability to execute multi-quarter product adoption plans reliably.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.47 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$6.91B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Aug 28, 2026 which is in 75 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Mar 31, 2026. The company reported HK$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.023.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of HK$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.71%
12-Months-Change
Fundamentals
Return on Equity
4.06%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company founded in 1999 and based in Shenzhen, People's Republic of China, focuses on the research, production, and distribution of interventional medical devices. These advanced technologies are utilized in treating ailments of the cardiovascular and peripheral vascular systems. The company's operations are structured across three primary divisions: Structural Heart Diseases, Peripheral Vascular Diseases, and Cardiac Pacing and Electrophysiology. Its extensive product range features innovative solutions such as the LAmbre left atrial appendage closure systems, a variety of VSD occluders (including CeraFlex, Cera, Heart, and Konara-MF), and Ankura stent graft systems for both thoracic and abdominal aortic aneurysms. LifeTech also provides critical auxiliary components like Fustar steerable and SteerEase introducers, in addition to devices such as Aegisy vena cava filters, Cera vascular plug systems, AcuMark sizing balloons, LawMax dilators, SeQure snare systems, and pacemakers. Beyond its core medical device activities, the corporation engages in biomedical research and development, the manufacturing and trade of various materials (including those related to hemp), internal staff training and management, investor information consulting, and a suite of technical, advisory, and technological services. LifeTech Scientific maintains a broad international presence, with business activities spanning Mainland China, India, the wider Asian region, Europe, South America, Africa, and other global territories.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---